Trumenba Side Effects

Generic name: meningococcal group B vaccine

Medically reviewed by Drugs.com. Last updated on Feb 13, 2024.

Note: This document provides detailed information about Trumenba Side Effects associated with meningococcal group B vaccine. Some dosage forms listed on this page may not apply specifically to the brand name Trumenba.

Applies to meningococcal group B vaccine: intramuscular suspension.

Important warnings This medicine can cause some serious health issues

You should not receive a booster vaccine if you had a life threatening allergic reaction after the first shot.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Keep track of all side effects you have. If you need a booster dose, you will need to tell the vaccination provider if the previous shot caused any side effects.

You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first shot.

Becoming infected with meningococcal disease and developing meningitis is much more dangerous to your health than receiving this vaccine. Any vaccine may cause side effects but the risk of serious side effects is low.

You may feel faint after receiving this vaccine. Some people have had seizure-like reactions after receiving this vaccine. Your doctor may want you to remain under observation during the first 15 minutes after the injection.

Common side effects may include:

• headache;

• feeling tired;

• muscle or joint pain;

• nausea, diarrhea; or

• pain, redness, swelling, or a hard lump where the shot was given.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For healthcare professionals

Applies to meningococcal group B vaccine: intramuscular suspension.

General

The most common adverse events were pain at the injection site, fatigue, erythema, myalgia, headache, and induration.^[Ref]

Local

• Very common (10% or more): Injection site pain (92.8%), erythema (50%), induration (32%), swelling (21.6%)
• Postmarketing reports: Blisters at or around injection site^[Ref]

Nervous system

• Very common (10% or more): Fatigue (64.4%), headache (56.9%), sleepiness, unusual crying
• Uncommon (0.1% to 1%): Seizures (including febrile seizures)
• Postmarketing reports: Syncope, vasovagal responses to injection^[Ref]

Musculoskeletal

• Very common (10% or more): Myalgia (49%), chills (30.3%), arthralgia (21.6%)^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (19%), diarrhea (15.2%)
• Common (1% to 10%): Vomiting^[Ref]

Psychiatric

• Very common (10% or more): Irritability^[Ref]

Metabolic

• Very common (10% or more): Eating disorders^[Ref]

Other

• Common (1% to 10%): Fever^[Ref]

Dermatologic

• Common (1% to 10%): Rash
• Uncommon (0.1% to 1%): Eczema
• Rare (less than 0.1%): Urticaria^[Ref]

Cardiovascular

• Uncommon (0.1% to 1%): Pallor (rare after booster)
• Rare (less than 0.1%): Kawasaki syndrome^[Ref]

Hypersensitivity

• Very rare (less than 0.01%): Anaphylaxis
• Postmarketing reports: Allergic reactions, rash, eye swelling^[Ref]

Respiratory

• Frequency not reported: Nasopharyngitis^[Ref]

Further information

Trumenba side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer